Higher Colleges of Technology, Al Ain, UAE. ; The Wharton Entrepreneurship and Family Business Research Centre, University of Pennsylvania, CERT Technology Park, Abu Dhabi, UAE.
Int J Health Policy Manag. 2014 Nov 6;3(7):365-70. doi: 10.15171/ijhpm.2014.118. eCollection 2014 Dec.
The objective of this work is to elucidate various essential drugs in the Brazil, Russia, India, China and South Africa (BRICS) countries. It discusses the opportunities and challenges of the existing biotech infrastructure and the production of drugs and vaccines in member states of the BRICS. This research is based on a systematic literature review between the years 2000 and 2014 of documents retrieved from the databases Embase, PubMed/Medline, Global Health, and Google Scholar, and the websites of relevant international organizations, research institutions and philanthropic organizations. Findings vary from one member state to another. These include useful comparison between the BRICS countries in terms of pharmaceuticals expenditure versus total health expenditure, local manufacturing of drugs/vaccines using technology and know-how transferred from developed countries, and biotech entrepreneurial collaborations under the umbrella of the BRICS region. This study concludes by providing recommendations to support more of inter collaborations among the BRICS countries as well as between BRICS and many developing countries to shrink drug production costs. In addition, this collaboration would also culminate in reaching out to poor countries that are not able to provide their communities and patients with cost-effective essential medicines.
本研究旨在阐明巴西、俄罗斯、印度、中国和南非（金砖国家）中的基本药物。文中讨论了金砖国家现有生物技术基础设施和药物及疫苗生产的机遇与挑战。该研究基于对 2000 年至 2014 年间从 Embase、PubMed/Medline、全球卫生和 Google Scholar 数据库以及相关国际组织、研究机构和慈善组织网站中检索到的文件进行的系统文献综述。研究结果因成员国的不同而有所差异。这些成员国包括在药品支出与总卫生支出的对比、使用从发达国家转移的技术和专门知识进行本地药物/疫苗生产、以及在金砖国家地区框架下开展生物技术创业合作等方面的有益比较。本研究最后提出建议，以支持金砖国家之间以及金砖国家与许多发展中国家之间开展更多的合作，降低药物生产成本。此外，这种合作还将有助于向无法为其社区和患者提供经济有效的基本药物的贫穷国家提供援助。
